CAJ | 학술논문

目的：评价伊立替康联合表柔比星治疗铂类耐药型卵巢上皮癌的临床疗效及不良反应。方法选取19例铂类耐药卵巢癌患者，给予伊立替康联合表柔比星治疗，评价临床疗效及不良反应。结果19例患者总缓解率26.4%，中位生存时间15个月。突出的不良反应为Ⅲ~Ⅳ度白细胞减少和迟发性腹泻。结论伊立替康联合表柔比星治疗铂类耐药卵巢癌具有较好疗效，不良反应可耐受，值得推广应用。
목적：평개이립체강연합표유비성치료박류내약형란소상피암적림상료효급불량반응。방법선취19례박류내약란소암환자，급여이립체강연합표유비성치료，평개림상료효급불량반응。결과19례환자총완해솔26.4%，중위생존시간15개월。돌출적불량반응위Ⅲ~Ⅳ도백세포감소화지발성복사。결론이립체강연합표유비성치료박류내약란소암구유교호료효，불량반응가내수，치득추엄응용。
Objective To evaluate the curative effect and adverse reaction of irinotecan combined with epirubicin in treatment of platinum-resistant ovarian cancer. Methods 19 cases of platinum-resistant ovarian cancer were treated by irinotecan combined with epirubicin, observing the effects and the side-effects.Results The total effective rate was 26.4%, median survival time was 15 months. The main side-effects wereⅢ/Ⅳ leucocytopenia and tardive diarrhea.Conclusion Irinotecan combined with epirubicin is a utility and safe regimen for platinum-resistant ovarian cancer. All adverse reactions can be tolerated. It can be popularized in clinical.